Relypsa, Inc. (RLYP) Completes Enrollment Of Phase 1 Onset-Of-Action Study For Patiromer
2/5/2014 9:31:05 AM
REDWOOD CITY, Calif., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a clinical-stage biopharmaceutical company, today announced that patient enrollment for its Phase 1 onset-of-action trial of patiromer for the treatment of hyperkalemia has been completed. This is the final clinical trial that Relypsa expects to include in its New Drug Application (NDA), planned to be filed with the U.S. Food and Drug Administration (FDA) during the third quarter of 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by